Search Results

There are 4156 results for: content related to: UGT1A1*6 , 1A7*3 , and 1A9*22 genotypes predict severe neutropenia in FOLFIRI -treated metastatic colorectal cancer in two prospective studies in Japan

  1. You have full text access to this Open Access content
    Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer

    Cancer Science

    Volume 97, Issue 11, November 2006, Pages: 1255–1259, Kazuhiro Araki, Ken-ichi Fujita, Yuichi Ando, Fumio Nagashima, Wataru Yamamoto, Hisashi Endo, Toshimichi Miya, Keiji Kodama, Masaru Narabayashi and Yasutsuna Sasaki

    Article first published online : 12 SEP 2006, DOI: 10.1111/j.1349-7006.2006.00321.x

  2. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert’s syndrome in Taiwanese adults

    Clinical Genetics

    Volume 72, Issue 4, October 2007, Pages: 321–328, H-C Teng, M-J Huang, K-S Tang, S-S Yang, C-S Tseng and C-S Huang

    Article first published online : 6 AUG 2007, DOI: 10.1111/j.1399-0004.2007.00873.x

  3. You have full text access to this Open Access content
    Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients

    Cancer Science

    Volume 98, Issue 9, September 2007, Pages: 1461–1467, Srinivasa Rao Jada, Robert Lim, Chiung Ing Wong, Xiaochen Shu, Soo Chin Lee, Qingyu Zhou, Boon Cher Goh and Balram Chowbay

    Article first published online : 11 JUL 2007, DOI: 10.1111/j.1349-7006.2007.00541.x

  4. Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers

    Journal of Clinical Laboratory Analysis

    Chonlaphat Sukasem, Chalirmporn Atasilp, Pichai Chansriwong, Montri Chamnanphon, Apichaya Puangpetch and Ekapob Sirachainan

    Article first published online : 26 DEC 2014, DOI: 10.1002/jcla.21820

  5. You have full text access to this OnlineOpen article
    Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice


    Volume 56, Issue 2, August 2012, Pages: 658–667, Shujuan Chen, Mei-Fei Yueh, Ronald M. Evans and Robert H. Tukey

    Article first published online : 11 JUN 2012, DOI: 10.1002/hep.25671

  6. You have full text access to this OnlineOpen article
    Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

    Cancer Science

    Volume 105, Issue 10, October 2014, Pages: 1321–1326, Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama and Narikazu Boku

    Article first published online : 29 SEP 2014, DOI: 10.1111/cas.12501

  7. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 3, June 2015, Pages: 219–237, Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec and Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx)

    Article first published online : 4 MAY 2015, DOI: 10.1111/fcp.12117

  8. You have full text access to this Open Access content
    Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

    Cancer Science

    Volume 102, Issue 10, October 2011, Pages: 1868–1873, Taroh Satoh, Takashi Ura, Yasuhide Yamada, Kentaro Yamazaki, Toshimasa Tsujinaka, Masaki Munakata, Tomohiro Nishina, Shu Okamura, Taito Esaki, Yasutsuna Sasaki, Wasaburo Koizumi, Yoshihiro Kakeji, Naoki Ishizuka, Ichinosuke Hyodo and Yuh Sakata

    Article first published online : 12 AUG 2011, DOI: 10.1111/j.1349-7006.2011.02030.x

  9. Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 6, June 2009, Pages: 623–627, LA Wenning, AS Petry, JT Kost, B Jin, SA Breidinger, I DeLepeleire, EJ Carlini, S Young, T Rushmore, F Wagner, NM Lunde, F Bieberdorf, H Greenberg, JA Stone, JA Wagner and M Iwamoto

    Article first published online : 11 MAR 2009, DOI: 10.1038/clpt.2009.12

  10. UDP-Glucuronosyltransferases: Pharmacogenetics, Functional Characterization, and Clinical Relevance

    Standard Article

    Encyclopedia of Drug Metabolism and Interactions

    Robert S. Foti and Michael B. Fisher

    Published Online : 31 JAN 2012, DOI: 10.1002/9780470921920.edm015

  11. You have free access to this content
    Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk


    Volume 98, Issue 4, 15 August 2003, Pages: 872–880, Abul Elahi, Jean Bendaly, Zhong Zheng, Joshua E. Muscat, John P. Richie Jr., Stimson P. Schantz and Philip Lazarus

    Article first published online : 1 JUL 2003, DOI: 10.1002/cncr.11587

  12. Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications

    Clinical Pharmacology & Therapeutics

    Volume 96, Issue 3, September 2014, Pages: 324–339, C Guillemette, É Lévesque and M Rouleau

    Article first published online : 12 JUN 2014, DOI: 10.1038/clpt.2014.126

  13. You have free access to this content
    Gilbert syndrome redefined: A complex genetic haplotype influences the regulation of glucuronidation


    Volume 55, Issue 6, June 2012, Pages: 1912–1921, Ursula Ehmer, Sandra Kalthoff, Bastian Fakundiny, Brigitte Pabst, Nicole Freiberg, Ronald Naumann, Michael P. Manns and Christian P. Strassburg

    Article first published online : 23 APR 2012, DOI: 10.1002/hep.25561

  14. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions

    Genes, Chromosomes and Cancer

    Volume 53, Issue 6, June 2014, Pages: 454–466, Andrea Y. Angstadt, Terryl J. Hartman, Samuel M. Lesko, Joshua E. Muscat, Junjia Zhu, Carla J. Gallagher and Philip Lazarus

    Article first published online : 12 FEB 2014, DOI: 10.1002/gcc.22157

  15. Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk

    Head & Neck

    Volume 35, Issue 6, June 2013, Pages: 858–867, Martin Lacko, Adri C. Voogd, Hennie M. J. Roelofs, Rene H. M. te Morsche, Michel B. Oude Ophuis, Wilbert H. M. Peters and Johannes J. Manni

    Article first published online : 19 JUN 2012, DOI: 10.1002/hed.23054

  16. The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

    Clinical Pharmacology & Therapeutics

    Volume 78, Issue 4, October 2005, Pages: 351–361, Dirk R. J. Kuypers, Maarten Naesens, Severine Vermeire and Yves Vanrenterghem

    Article first published online : 5 OCT 2005, DOI: 10.1016/j.clpt.2005.06.007

  17. UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients

    Clinical Pharmacology & Therapeutics

    Volume 86, Issue 3, September 2009, Pages: 319–327, R H N van Schaik, M van Agteren, J W de Fijter, A Hartmann, J Schmidt, K Budde, D Kuypers, Y Le Meur, M van der Werf, R Mamelok and T van Gelder

    Article first published online : 3 JUN 2009, DOI: 10.1038/clpt.2009.83

  18. Phase I/II Pharmacokinetic and Pharmacogenomic Study of UGT1A1 Polymorphism in Elderly Patients With Advanced Non–Small Cell Lung Cancer Treated With Irinotecan

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 2, February 2009, Pages: 149–154, N Yamamoto, T Takahashi, H Kunikane, N Masuda, K Eguchi, M Shibuya, Y Takeda, H Isobe, T Ogura, A Yokoyama and K Watanabe

    Article first published online : 6 AUG 2008, DOI: 10.1038/clpt.2008.152

  19. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1067–1075, Ana B. Santoro, Daniela D. Vargens, Mateus de Camargo Barros Filho, Daniel A. Bulzico, Luiz Paulo Kowalski, Ricardo M. R. Meirelles, Daniela P. Paula, Ronaldo R. S. Neves, Cencita N. Pessoa, Claudio J. Struchine and Guilherme Suarez-Kurtz

    Article first published online : 20 OCT 2014, DOI: 10.1111/bcp.12437

  20. The Role of SN-38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

    The Journal of Clinical Pharmacology

    Volume 47, Issue 1, January 2007, Pages: 78–86, Dr Roshni P. Ramchandani, Dr Yaning Wang, Dr Brian P. Booth, Dr Amna Ibrahim, Dr John R. Johnson, Dr Atiqur Rahman, Dr Mehul Mehta, Dr Federico Innocenti, Dr Mark J. Ratain and Dr Jogarao V. S. Gobburu

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270006295060